Pfizer Inc.
PFE
주식 순위
#110
Pfizer Inc. is a global biopharmaceutical leader engaged in the research,... Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
주가
$30.16
시가총액
$171.87B
변동 (1일)
2.34%
변동 (1년)
22.13%
국가
US
거래 Pfizer Inc. (PFE)
카테고리
Healthcare
Pfizer Inc. (PFE)의 매출
Jun 2026 기준 매출 TTM: $63.70B
Pfizer Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $63.70B입니다. 2024년에 회사는 $63.63B의 수익을 올렸으며 이는 2023년의 $59.55B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Pfizer Inc.의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $63.70B | 1.78% |
| 2025 | $62.58B | -1.65% |
| 2024 | $63.63B | 6.84% |
| 2023 | $59.55B | -40.64% |
| 2022 | $100.33B | 23.43% |
| 2021 | $81.29B | 95.16% |
| 2020 | $41.65B | 1.16% |
| 2019 | $41.17B | -23.25% |
| 2018 | $53.65B | 2.10% |
| 2017 | $52.55B | -0.53% |
| 2016 | $52.82B | 8.13% |
| 2015 | $48.85B | -1.52% |
| 2014 | $49.61B | -3.84% |
| 2013 | $51.58B | -5.62% |
| 2012 | $54.66B | -10.45% |
| 2011 | $61.04B | -8.98% |
| 2010 | $67.06B | 34.09% |
| 2009 | $50.01B | 3.55% |
| 2008 | $48.30B | -0.27% |
| 2007 | $48.43B | 0.12% |
| 2006 | $48.37B | 2.04% |
| 2005 | $47.41B | -9.73% |
| 2004 | $52.52B | 16.22% |
| 2003 | $45.19B | 39.59% |
| 2002 | $32.37B | 0.35% |
| 2001 | $32.26B | 9.08% |
| 2000 | $29.57B | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $79.67B | 25.07% |
US
|
|
| $99.34B | 55.95% |
US
|
|
| $64.39B | 1.08% |
US
|
|
| $66.40B | 4.25% |
US
|
|
| $77.52B | 21.70% |
CH
|
